Affiliation:
1. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada
2. Department of Biostatistics, Princess Margaret Cancer Centre University Health Network Toronto Ontario Canada
Abstract
AbstractNucleophosmin‐1 (NPM1)‐mutated AML is a molecularly defined subtype typically associated with favorable treatment response and prognosis; however, its prognostic significance in AML evolving from an antecedent chronic myeloid malignancy is unknown. This study's primary objective was to determine the impact of mutated NPM1 on the prognosis of AML evolving from an antecedent chronic myeloid malignancy. We conducted a retrospective chart review including patients with NPM1‐mutated de novo and sAML. sAML was defined as those with a preceding chronic‐phase myeloid malignancy before diagnosis of AML. Of 575 NPM1‐mutated patients eligible for inclusion in our study, 51 (8.9%) patients were considered to have sAML. The median time from diagnosis of NPM1‐mutated chronic myeloid malignancy to sAML evolution was 3.6 months (0.5–79.3 months). No significant differences in leukemia‐free (2‐year LKFS 52.0% vs. 51.2%, p = .9922) or overall survival (2‐year OS 56.3% vs. 49.4%, p = .4246) were observed between patients with NPM1‐mutated de novo versus sAML. Our study suggests that evolution from a preceding myeloid malignancy is not a significant predictor of poor prognosis in the setting of an NPM1 mutation. Our study demonstrated a short time to progression to sAML in most patients, which further supports the consideration of NPM1 as an AML‐defining mutation.